U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H23BrFNO2
Molecular Weight 420.315
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BROMPERIDOL

SMILES

OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C3=CC=C(Br)C=C3

InChI

InChIKey=RKLNONIVDFXQRX-UHFFFAOYSA-N
InChI=1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2

HIDE SMILES / InChI
Molecular Formula C21H23BrFNO2
Molecular Weight 420.315
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Bromperidol decanoate is a long-acting antipsychotic medication used in at least Belgium, Germany, Italy, and the Netherlands. In clinical trials, Bromperidol decanoate was effective in the treatment of residual schizophrenia, with significant differences between before and after treatment ratings for symptoms. The preparation seems to be less potent than other depot antipsychotics (such as fluphenazine and haloperidol decanoate) and better than placebo injection. If bromperidol decanoate is available to the clinician it may be a viable choice, especially when there are reasons not to use fluphenazine or haloperidol decanoate.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
Antagonist
2778
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Clinical experiences in an open and a double-blind trial.
1978 Jan-Feb
Double-blind- evaluation of bromperidol versus haloperidol treatment in chronic psychotic patients.
1978 Jan-Feb
The initial US clinical experience in the management of schizophrenic patients with bromperidol.
1978 Jan-Feb
Clinical evaluation of bromperidol versus haloperidol in psychotic patients.
1980
Neuroleptic malignant syndrome after clozapine plus carbamazepine.
1988 Dec 24-31
Possible interaction between cisapride and bromperidol.
1997 Jan
[Involvement of cytochromeP4503A4 in the metabolism of haloperidol and bromperidol].
1998 Feb
Lesioning the thalamus for dyskinesia.
2001
The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients.
2001 Aug
[Malignant syndrome caused by a combination of bromperidol and donepezil hydrochloride in a patient with probable dementia with Lewy bodies].
2001 Nov
Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients.
2002 Apr
Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms.
2002 Jan
Switching to amisulpride due to hepatic complications.
2002 May
Poor reliability of therapeutic drug monitoring data for haloperidol and bromperidol using enzyme immunoassay.
2003 Dec
Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization.
2003 Mar
[Frontal dementia or dementia praecox? A case report of a psychotic disorder with a severe decline].
2003 Mar-Apr
Combination of dopamine D2 receptor gene polymorphisms as a possible predictor of treatment-resistance to dopamine antagonists in schizophrenic patients.
2003 Sep
Depot bromperidol decanoate for schizophrenia.
2004
Establishment of new cloned enzyme donor immunoassays (CEDIA) for haloperidol and bromperidol.
2004 Jun
Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain.
2004 Nov 26
Effect of quetiapine in the treatment of panic attacks in patients with schizophrenia: 3 case reports.
2004 Winter
Pharmacokinetic parameters of bromperidol in Korean subjects.
2006 Aug
Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study.
2006 Mar
Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians.
2007 Dec
Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.
2007 Jun
The effects of atypical and conventional antipsychotics on reduced processing speed and psychomotor slowing in schizophrenia: a cross-sectional exploratory study.
2008 Apr
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
2008 Dec 22
Drugs associated with more suicidal ideations are also associated with more suicide attempts.
2009 Oct 2
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
Screening of a chemical library reveals novel PXR-activating pharmacologic compounds.
2015 Jan 5
Patents

Patents

EP0454773
2

Sample Use Guides

In Vivo Use Guide
Oral Schizophrenia: Adult: 1-15 mg daily, up to 50 mg daily. Intramuscular Schizophrenia: Adult: Long-term therapy: Up to 300 mg every 4 wk via deep inj. Intramuscular Psychoses: Adult: Long-term therapy: Up to 300 mg every 4 wk via deep inj. Oral Psychoses: Adult: 1-15 mg daily, up to 50 mg daily.
Route of Administration: Other
In Vitro Use Guide
Curator's Comment: In in vivo and in vitro experiements the antidopaminergic action of bromperidol, evaluated by PRL release, can be considered intermediate between pimozide and haloperidol.
Bromperidol is able to antagonize as well as haloperidol the DA-induced LH-RH release.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:00:21 UTC 2023
Edited
by admin
on Fri Dec 15 15:00:21 UTC 2023
Record UNII
LYH6F7I22E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BROMPERIDOL
EP   INN   JAN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
R-11333
Code English
1-BUTANONE, 4-(4-(4-BROMOPHENYL)-4-HYDROXY-1-PIPERIDINYL)-1-(4-FLUOROPHENYL)-
Systematic Name English
BROMPERIDOL [EP MONOGRAPH]
Common Name English
NSC-759275
Code English
BROMPERIDOL [MART.]
Common Name English
BROMPERIDOL [MI]
Common Name English
R 11,333
Code English
BROMPERIDOL [JAN]
Common Name English
4-(4-(P-BROMOPHENYL)-4-HYDROXYPIPERIDINO)-4'-FLUOROBUTYROPHENONE
Common Name English
IMPROMEN
Brand Name English
BROMPERIDOL [USAN]
Common Name English
BROMPERIDOL DECANOATE IMPURITY G [EP IMPURITY]
Common Name English
bromperidol [INN]
Common Name English
Bromperidol [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29710
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
WHO-VATC QN05AD06
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
WHO-ATC N05AD06
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
Code System Code Type Description
EVMPD
SUB05923MIG
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
INN
3737
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
DRUG CENTRAL
407
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
SMS_ID
100000091973
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
EPA CompTox
DTXSID0022690
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
NCI_THESAURUS
C76439
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
DRUG BANK
DB12401
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
FDA UNII
LYH6F7I22E
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
MERCK INDEX
m2722
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY Merck Index
MESH
C006820
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
WIKIPEDIA
BROMPERIDOL
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
NSC
759275
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
ECHA (EC/EINECS)
233-943-3
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
RXCUI
19777
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY RxNorm
CAS
10457-90-6
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
ChEMBL
CHEMBL28218
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
PUBCHEM
2448
Created by admin on Fri Dec 15 15:00:21 UTC 2023 , Edited by admin on Fri Dec 15 15:00:21 UTC 2023
PRIMARY
Related Record Type Details
D(2) DOPAMINE RECEPTOR
TARGET -> INHIBITOR
Ki
D(3) DOPAMINE RECEPTOR
TARGET -> INHIBITOR
Ki
5-HYDROXYTRYPTAMINE RECEPTOR 2A
TARGET -> INHIBITOR
Ki
Related Record Type Details
Structure of BROMPERIDOL DECANOATE
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
Structure of BROMPERIDOL DECANOATE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of BROMPERIDOL
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966